AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05208762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08046054
Description: Given into the vein (IV; intravenously)
Study NCT05208762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg once every 3 weeks given into the vein (IV; intravenously)
Study NCT05480787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 0.1mg/kg/h
Description: Remimazolam Tosilate for Injection(36mg)
Study NCT05480787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 0.3mg/kg/h
Description: Remimazolam Tosilate for Injection(36mg)
Study NCT05480787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam 0.5mg/kg/h
Description: Remimazolam Tosilate for Injection(36mg)
Study NCT04806932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The modified approach
Description: The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
Study NCT04806932 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: The conventional approach
Description: The conventional approach
Study NCT06034847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rescue mechanical thrombectomy in distal vessels
Description: In addition to mechanical thrombectomy in proximal large vessels, mechanical thrombectomy in distal vessels with small stent retrievers combined or not with contact aspiration, or intra-arterial perfusion of thrombolytics such as tPA or uPA or tenecpeplase
Study NCT05485454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aria Health Aria Free
Description: An in-clinic therapy session with the Aria Free for a duration of 30 minutes under the direct supervision of the Principal Investigator.
Study NCT05485454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A Traditional PCD
Description: An in-clinic therapy session with the traditional PCD for a duration of 30 minutes under the direct supervision of the Principal Investigator.
Study NCT04619927 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Direct CYP2C19 genotyping
Description: CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
Study NCT04619927 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 genotyping at the end of the study
Description: Blood-based CYP2C19 genotyping will be performed at the end of the study
Study NCT04619927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poor metabolisers
Description: Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
Study NCT04619927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate metabolisers
Description: Clopidogrel 75mg twice daily
Study NCT04619927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal metabolisers and unknown metaboliser state
Description: Clopidogrel 75mg once daily
Study NCT04619927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal metabolisers and unknown metaboliser state
Description: Clopidogrel 75mg once daily
Study NCT06613464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnosis confirmation
Description: The patients diagnoses will be confirmed though imaging methods like computed tomography chest x-ray and anamnesis
Study NCT06613425 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined platelets
Description: 1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.
Study NCT06609850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
Study NCT06609850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
Study NCT06609850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.
Study NCT06609850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinb
Description: Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
Study NCT06609850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinb
Description: Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
Study NCT06421831 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC101
Description: Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
Study NCT05878795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WET-SP
Description: WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 45 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
Study NCT05878795 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
Study NCT05878795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
Study NCT05720104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
Study NCT05720104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard oral hygiene instructions
Description: Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
Study NCT05720104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene instructions
Description: Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
Study NCT06498479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20093
Description: HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
Study NCT06498479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per drug label.
Study NCT06554821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin (dose 1 or dose 2) orally as a single dose on Day 1 in Period 1 and Day 6 in Period 2.
Study NCT06554821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Participants in each arm will receive ticagrelor 90 mg orally BID from Day 6 to Day 10.
Study NCT06598852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPVB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB Group received thoracic paravertebral nerve block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
Study NCT06598852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESPB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ESPB Group received erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
Study NCT06598852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TPVB combined ESPB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in TPVB combined ESPB group received thoracic paravertebral block combined with erector spinae muscle block with 0.33% ropivacaine 30ml under ultrasound guidance after anesthesia induction for postoperative analgesia.
Study NCT06598852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICNB group
Description: Patients undergoing thoracoscopic surgery underwent general anesthesia and patients in ICNB Group received intercostal nerve block for postoperative analgesia.
Study NCT06614348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate eye drop group
Description: Patients receive prednisolone acetate eye drops 4 times per 30min within 2 hours before cataract surgery
Study NCT06614348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium hyaluronate eye drops
Description: Patients receive sodium hyaluronate eye drops 4 times per 30min within 2 hours before cataract surgery
Study NCT04968574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taladegib
Description: hedgehog pathway inhibitor dosed once daily
Study NCT04968574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical tablets to the experimental arm with no active ingredient
Study NCT06627582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS Scale v2.0 - Pain Intensity 3a
Description: PROMIS Scale v2.0 - Pain Intensity 3a is a 3-question short form in which patients rate their worst, average, and current level of pain during the past 7 days.
Study NCT06627582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS 29+2
Description: PROMIS 29+2 (PROMIS-Preference, PROPr) is a compilation of item banks to assess pain intensity
Study NCT06627582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS Scale v2.0 - Nociceptive Pain Quality 5a
Description: 5-question short form that identifies patients who have experienced nociceptive pain during the past 7 days
Study NCT06627582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS Scale v2.0 - Neuropathic Pain Quality 5a
Description: 5-question short form that identifies patients who have experienced neuropathic pain during the past 7 days
Study NCT06622148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Description: For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) .
Study NCT06622148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)
Description: For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by AMERICAN REGENT, INC.) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
Study NCT06626334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Blue Light
Description: Bright blue light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#132, Medium Blue) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
Study NCT06626334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Full-Spectrum (White) Light
Description: Bright full-spectrum (white) light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#211 0.9 ND) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
Study NCT06626334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usual Ambient Light
Description: Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days.
Study NCT06626334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Ambient Light
Description: Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days.
Study NCT06626334 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Ambient Light
Description: Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days.
Study NCT05177341 — intervention group
Intervention type: OTHER
Intervention: Determining Preferred Walking Speed
Description: In the beginning, sensors of the gait analysis system (RehaGait®), which can record the time-distance characteristics of consecutive multiple steps (step length, step width, double step length, and timing information, etc.) will be installed. The 7 sensors of this system are attached to the shoes of the individual, proximal to the ankle, distal thigh, and sacroiliac joint level (Aminian et al., 2014). Individuals will be required to wear casual athletic shoes and comfortable, non-knee-covering shorts. Next; Each individual will walk freely on the treadmill at their own pace. To find the preferred walking speed of the individual, Hinton et al. protocol will be used (Hinton et al., 2018). The speed of the treadmill will be increased or decreased in line with the direction of the participants. After being determined according to the protocol, the individual will practice walking at this speed for 4-5 minutes. The individual will rest as much as he or she wants.
Study NCT06632015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment and intracanal medicament
Description: Root canal treatment and intracanal medicament procedures explained in arm descriptions.
Study NCT06176755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with weighted ankle cuffs
Description: Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently.
Study NCT06176755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Treadmill training only
Study NCT05445076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody, low dose
Description: infusion
Study NCT05445076 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: anti-TRBV9 monoclonal antibody, low dose
Description: infusion
Study NCT05445076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TRBV9 monoclonal antibody, high dose
Description: infusion
Study NCT05445076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion
Study NCT06632015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal treatment and intracanal medicament
Description: Root canal treatment and intracanal medicament procedures explained in arm descriptions.
Study NCT06628882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular Block
Description: types of anesthesia used in upper extremity surgeries
Study NCT06628882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide-Awake Local Anesthesia with No Tourniquet
Description: types of anesthesia used in upper extremity surgeries
Study NCT06630559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P55
Description: CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
Study NCT06630559 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P55
Description: CT-P55, 300 mg by 2 subcutaneous (SC) injections of 150 mg/mL via Pre-Filled Syringe (PFS) every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by every 4 weeks (Q4W) for 11doses (up to Week 48).
Study NCT06630559 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Cosentyx
Description: European Union (EU)-approved Cosentyx, 300 mg by 2 SC injections of 150 mg/mL via PFS every week for 5 doses (up to Week 4 after starting dose at Day 1), followed by Q4W for 11 doses (up to Week 48).
Study NCT06629428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: The participants will receive 48 weeks of treatment with ublituximab.
Study NCT05423587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular Artery Embolisation
Description: Transarterial catheter directed embolisation of hypervascularity in patients with mild to moderate knee osteoarthritis
Study NCT05517525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.
Study NCT05423587 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genicular Artery Injection
Description: Transarterial catheter directed injection of normal (0.9%) saline in patients with mild to moderate knee osteoarthritis